Source comparison
BPC-157 LL-37 Protocol Chronic Infection Research: Study Comparison
Diabetic foot ulcer (murine, 2024) 250 mcg/kg SC 10 mcg/mL topical gel Wound closure time 3.2 log CFU/g (combination) vs 0.7 log (BPC-157 alone) Capillary density +89% at 48h Combination showed clear synergy. Neither peptide alone achieved >1.5 log reduction O
This comparison does not assign a generated winner or score.
- Diabetic foot ulcer (murine, 2024)
- 250 mcg/kg SC
- 10 mcg/mL topical gel
- Wound closure time
- 3.2 log CFU/g (combination) vs 0.7 log (BPC-157 alone)
- Capillary density +89% at 48h
- Combination showed clear synergy. Neither peptide alone achieved >1.5 log reduction
- Osteomyelitis (rat, 2023)
- 500 mcg/kg IP
- 20 mcg/mL intraosseous
- Bone density restoration
- 2.8 log CFU/g bone tissue
- Trabecular bone density +22% at 14 days
- High-dose LL-37 caused local inflammation. 10 mcg/mL may be optimal for bone applications
- Biofilm disruption (P. aeruginosa, in vitro, 2023)
- Not tested
- 5–50 mcg/mL
- Biofilm mass reduction
- 64% reduction at 20 mcg/mL
- N/A (in vitro model)
- LL-37 alone insufficient for established infections. Requires immune recruitment that in vitro models can't assess
- Chronic wound infection (porcine, 2022)
- 300 mcg/kg SC
- 15 mcg/mL topical
- Epithelialization rate
- 1.9 log CFU/g tissue
- Re-epithelialization +53% vs control
- Porcine skin closely models human tissue. Dosing here translates well to human protocols